• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16524 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Auditory screening and hearing loss prevention: a review of the clinical evidence and guidelines
2011     HAYES, Inc. Tandem autologous peripheral blood stem cell transplantation for neuroblastoma
2011     Technology Assessment Unit of the McGill University Health Centre (MUHC) Subglottic secretion drainage endotracheal tubes for prevention of ventilator-associated pneumonia
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Upper extremity deep vein thrombosis with peripherally inserted central catheters: a review of the guidelines
2011     HAYES, Inc. Ultroid hemorrhoid management system (Ultroid Technologies Inc.)
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Cardiac output monitors to assess patient resuscitation needs: a review of clinical effectiveness and cost-effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Multidisciplinary medication review in long term care: a review of the clinical evidence and guidelines
2011     Technology Assessment Unit of the McGill University Health Centre (MUHC) Aortic valve bypass (apicoaortic conduit) in adult degenerative aortic stenosis
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Metabolic monitoring and interventions for reducing metabolic syndrome in patients treated with atypical antipsychotics: a review of the clinical evidence
2011     Health Technology and Policy Unit (HTPU) Middle ear implants for the treatment of hearing loss
2011     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Facet joint injection as diagnostic and therapeutic tools for pain of the cervical and lumbar spine: a review of clinical and cost-effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines
2011     Health Technology and Policy Unit (HTPU) Photodynamic therapy for skin cancer & pre-cancerous skin conditions
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Management and patient safety of IVIG administration: a review of clinical practice guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) T-score as a measurement to assess the 10-year fracture risk: a review of the clinical evidence
2011     HTA Unit, University of Calgary Health technology reassessment and reinvestment: a systematic review of current practices
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Pediatric supraglottic airway devices: a review of clinical effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Adrenal suppression and clinical harms by inhaled corticosteroids: a review of safety and guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Robotic surgery versus open-chest surgery for internal mammary artery harvesting and mitral valve surgery: clinical effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Acetylsalicylic acid for venous thromboembolism prophylaxis: a review of clinical evidence, benefits and harms
2011     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) In vitro test for the evaluation of individual risk of metastasis in surgically treated women for breast cancer
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Feeding tube verification procedures: optimal timing and guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Phallometric assessment of sex offenders: a review of the clinical evidence and guidelines
2011     NIHR Health Technology Assessment programme Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-adherent versus traditional dressings for wound care: comparative effectiveness, safety, and guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone for short-term detoxification: a review of the clinical evidence
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Intravenous insulin infusions in labouring women: guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Combination Benzodiazepine-Opioid use: a review of the evidence on safety
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of fentanyl and continuous electronic fetal monitoring in labour and delivery: a review of clinical effectiveness, safety, and clinical practice guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Enzyme replacement therapy for rare diseases: a review of clinical efficacy
2011     NIHR Health Technology Assessment programme Liraglutide for the treatment of type 2 diabetes
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Antiviral stockpiling strategies for pandemic influenza: a review of the clinical and cost-effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence
2011     NIHR Health Technology Assessment programme Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Facet joint injection as diagnostic and therapeutic tools for pain of the cervical and lumbar spine: a review of clinical and cost-effectiveness
2011     NIHR Health Technology Assessment programme Golimumab for the treatment of ankylosing spondylitis
2011     Agency for Healthcare Research and Quality (AHRQ) Therapies for children with autism spectrum disorders.
2011     NIHR Health Technology Assessment programme An evidence synthesis of qualitative and quantitative research on component intervention techniques, effectiveness, cost-effectiveness, equity and acceptability of different versions of health-related lifestyle advisor role in improving health
2011     NIHR Health Technology Assessment programme Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
2011     Agency for Healthcare Research and Quality (AHRQ) Oral diabetes medications for adults with type 2 diabetes: an update
2011     NIHR Health Technology Assessment programme Bivalirudin for the treatment of ST-segment elevation myocardial infarction
2011     NIHR Health Technology Assessment programme Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation
2011     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
2011     Adelaide Health Technology Assessment (AHTA) Brachytherapy for the treatment of prostate cancer
2011     NIHR Health Technology Assessment programme Ticagrelor for the treatment of acute coronary syndromes
2011     Health Council of the Netherlands Gezondheidsraad (GR) Treating the effect of child abuse
2011     NIHR Health Technology Assessment programme Eribulin for the treatment of locally advanced or metastatic breast cancer
2011     Health Council of the Netherlands Gezondheidsraad (GR) Guidelines for a healthy diet: the ecological perspective
2011     NIHR Health Technology Assessment programme Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation
2011     NIHR Health Technology Assessment programme Fingolimod for the treatment of relapsing remitting multiple sclerosis
2011     NIHR Health Technology Assessment programme Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
2011     NIHR Health Technology Assessment programme VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers
2011     NIHR Health Technology Assessment programme Denosumab for osteoporotic fractures in post menopausal women primary and secondary prevention
2011     Medical Advisory Secretariat (MAS) Corneal collagen cross-linking using riboflavin and ultraviolet-A for corneal thinning disorders
2011     NIHR Health Technology Assessment programme Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing therapy
2011     NIHR Health Technology Assessment programme Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
2011     The Swedish Council on Health Technology Assessment (SBU) Treatment of hemophilia A and B and von willebrand disease
2011     Agency for Healthcare Research and Quality (AHRQ) Screening and treatment of subclinical hypothyroidism or hyperthyroidism
2011     NIHR Health Technology Assessment programme A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study)
2011     NIHR Health Technology Assessment programme Assessing the surgical skills of trainees in the operating theatre: a prospective observational study of the methodology
2011     NIHR Health Technology Assessment programme Mannitol dry powder for inhalation for the treatment of cystic fibrosis
2011     The Swedish Council on Health Technology Assessment (SBU) Medical and psychological methods for preventing sexual offences against children
2011     Agency for Healthcare Research and Quality (AHRQ) Role of active surveillance in the management of men with localized prostate cancer
2011     NIHR Health Technology Assessment programme The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department
2011     NIHR Health Technology Assessment programme Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus
2011     The Swedish Council on Health Technology Assessment (SBU) Computed tomography for suspected coronary artery disease
2011     NIHR Health Technology Assessment programme Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses
2011     NIHR Health Technology Assessment programme Fulvestrant for the treatment of locally advanced or metastatic breast cancer
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Long versus short acting drugs for attention deficit/hyperactivity disorder in children and adolescents: a review of the guidelines and recommendations
2011     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation
2011     NIHR Health Technology Assessment programme Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Education classes for diabetes management: a review of the comparative clinical and cost-effectiveness
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rosuvastatin (Crestor®)
2011     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review
2011     NIHR Health Technology Assessment programme Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Functional Electrical Stimulation (FES) for children with spinal cord injuries: a review of the clinical effectiveness and guidelines
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paliperidone palmitate (Xeplion®)
2011     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
2011     NIHR Health Technology Assessment programme Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO): a single technology appraisal
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Dasatinib (Sprycel®)
2011     NIHR Health Technology Assessment programme EVerT: cryotherapy versus salicylic acid for the treatment of verrucae - a randomised controlled trial
2011     NIHR Health Technology Assessment programme Trabectedin for the treatment of relapsed ovarian cancer
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tapentadol prolonged release (Palexia® SR)
2011     NIHR Health Technology Assessment programme Accuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer
2011     NIHR Health Technology Assessment programme Roflumilast for the management of severe chronic obstructive pulmonary disease
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Antiplatelet agents for acute coronary syndrome: a review of the guidelines and recommendations
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Alteplase (Actilyse® Cathflo® 2 mg)
2011     NIHR Health Technology Assessment programme Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Calibration of blood glucose monitors for diabetes: a review of the clinical evidence and guidelines
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Saxagliptin (Onglyza®)
2011     NIHR Health Technology Assessment programme Hysterectomy, endometrial ablation and Mirena for heavy menstrual bleeding: a systematic review of clinical effectiveness and costeffectiveness analysis
2011     NIHR Health Technology Assessment programme Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines